Lobbying disclosures · Lobbying report
VRTX: third_quarter 2026 lobbying report
H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language Monitor issues related to 340b;
Follow VRTX- Became public
- Oct 20, 2026, 4:18 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 6:58 PM EST
Why this is connected
Legal-name match: VERTEX PHARMACEUTICALS INCORPORATED is VERTEX PHARMACEUTICALS INC / MA (https://www.sec.gov/Archives/edgar/data/875320/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/b3c13cd2-9786-4294-a726-b11ec500fc7c/","filing_uuid":"b3c13cd2-9786-4294-a726-b11ec500fc7c","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/b3c13cd2-9786-4294-a726-b11ec500fc7c/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tracy Spicer","dt_posted":"2026-10-20T16:18:19-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"401 9th St. NW","registrant_address_2":"Suite 720","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72111,"url":"https://lda.gov/api/v1/registrants/72111/","house_registrant_id":35940,"name":"AVENUE SOLUTIONS","description":"Government representation","address_1":"401 9th St. NW","address_2":"Suite 720","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY TEJRAL","contact_telephone":"+1 202-347-9848","dt_updated":"2026-07-30T13:56:38.410932-04:00"},"client":{"id":56875,"url":"https://lda.gov/api/v1/clients/56875/","client_id":56875,"name":"VERTEX PHARMACEUTICALS INCORPORATED","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-06-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48260,"prefix":"ms","prefix_display":"MS.","first_name":"ELIZABETH","nickname":null,"middle_name":"MACDONALD","last_name":"BARNETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Monitor issues related to 340b;","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48260,"prefix":"ms","prefix_display":"MS.","first_name":"ELIZABETH","nickname":null,"middle_name":"MACDONALD","last_name":"BARNETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in VRTX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 5, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Aug 26, 2026 · disclosed Sep 5, 2026
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- Feb 2, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 2, 2026
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Oct 23, 2024 · disclosed Jan 13, 2026 · filed 447 days later
- Sep 12, 2025$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Aug 26, 2025 · disclosed Sep 12, 2025 · Dependent
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.